Topoisomerase I interactive drugs in children with cancer

Clinton F. Stewart, William C. Zamboni, William R. Crom, Amar Gajjar, Richard L. Heideman, Wayne L. Furman, William H. Meyer, Peter J. Houghton, Charles B. Pratt

Research output: Contribution to journalReview article

39 Scopus citations

Abstract

Topotecan, irinotecan, and 9-aminocamptothecin (9-AC) are analogs of the plant alkaloid 20(S)-camptothecin (CMT), the prototypical DNA topoisomerase I interactive agent. These agents interact with the topoisomerase I-DNA complex and prevent resealing topoisomerase I-mediated DNA single-strand breaks. This eventual leads to double-strand DNA breaks and apoptosis or cell death. Topotecan, irinotecan, and 9-AC have shown significant activity in mice bearing pediatric solid tumor xenografts; the greatest antitumor responses were found with protracted continuous schedules. Preclinical data also suggest that maintenance of an exposure-duration threshold (EDT) may be required to achieve optimal cytotoxicity. Pediatric Phase I trials have evaluated the toxicity and safety of camptothecin analogs in children with relapsed solid tumors and relapsed acute leukemia. The primary dose-limiting toxicity (DLT) for the CMT analogs in children has been myelosuppression, except for mucositis observed with the 120-hr continuous topotecan infusion schedule. Pharmacodynamic relationships with these analogs have been reported between systemic exposure, and myelosuppression and mucositis. Although not a primary objective of the early Phase I studies, antitumor responses have been reported. In this review, the pharmacokinetics and pharmacodynamics of the CMT analogs studied in children are summarized, and future studies of these agents are discussed.

Original languageEnglish (US)
Pages (from-to)37-47
Number of pages11
JournalInvestigational New Drugs
Volume14
Issue number1
DOIs
StatePublished - Jan 1 1996
Externally publishedYes

    Fingerprint

Keywords

  • Camptothecin
  • DNA topoisomerase
  • Irinotecan
  • Pediatric oncology
  • Topotecan

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Stewart, C. F., Zamboni, W. C., Crom, W. R., Gajjar, A., Heideman, R. L., Furman, W. L., Meyer, W. H., Houghton, P. J., & Pratt, C. B. (1996). Topoisomerase I interactive drugs in children with cancer. Investigational New Drugs, 14(1), 37-47. https://doi.org/10.1007/BF00173681